Brain imaging study of antipsychotics in schizophrenia
Treatments studied
Part of Mental health clinical trials.
This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old
- You have been diagnosed with schizophrenia, schizoaffective, or schizophreniform disorder
- You have not taken any antipsychotic medication for at least 3 weeks (or 4 weeks if you were on aripiprazole or a long-acting injection)
- You have a moderate level of symptoms (PANSS score between 80 and 120)
- You are not pregnant, breastfeeding, or planning to become pregnant, and you use effective birth control
- You have not used nicotine products in the past month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early (Phase 1) study uses a special brain scan to look at synapses—the contact points between brain cells—in people with schizophrenia-related conditions. It helps researchers understand brain activity and connection patterns, which may guide future tests or treatments.
This study uses a special MRI technique to measure brain structure differences in people with schizophrenia, including those who also have nicotine dependence. Your participation could help researchers understand more about the condition.
This study measures brain signals during scans to look for patterns linked to two types (subforms) of psychotic disorders. If you have schizophrenia or schizoaffective disorder and your symptoms have been stable, you may be able to help researchers understand these brain markers.
This study uses a special brain scan (PET) to measure cannabinoid receptors—areas in the brain that interact with cannabis-like chemicals. It may help researchers better understand how these receptors relate to conditions such as schizophrenia, PTSD, opioid use disorder, or early psychosis risk.
This study uses brain scans (MRI and PET) to look at energy use and a brain chemical called glutamate in people with schizophrenia. It compares healthy volunteers to those with well-controlled schizophrenia and those with hard-to-treat schizophrenia to understand the biology better.
This is an observational (non-intervention) study that follows adults with schizophrenia who are taking specific “atypical” antipsychotic medicines long-term. Researchers want to learn about patients’ experiences and outcomes while on these treatments.
Hear when a new Schizoaffective Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.